Dr. reddy's laboratories announces the launch of difluprednate ophthalmic emulsion 0.05% in the u.s. market

Hyderabad, india & princeton, n.j.--( business wire )--dr. reddy's laboratories ltd. (bse: 500124, nse: drreddy, nyse: rdy, nseifsc: drreddy, along with its subsidiaries together referred to as “dr. reddy's”) today announced the launch of dr. reddy's difluprednate ophthalmic emulsion 0.05%, a therapeutic generic equivalent to durezol® (difluprednate ophthalmic emulsion 0.05%) in the u.s. market, following the approval by the u.s. food and drug administration (usfda).
RDY Ratings Summary
RDY Quant Ranking